eXmoor Pharma is a full-service Cell and Gene Therapy CDMO with a difference. Founded in 2004 and backed by more than 20 years of consultancy experience, eXmoor has supported over 170 organisations in accelerating therapies from discovery to delivery.
eXmoor combines strategic CMC consultancy, process development, analytical services and GMP manufacturing to provide comprehensive support across Viral Vectors, Autologous and Allogeneic Cell Therapies, and RNA technologies. This integrated model enables seamless progression from early-phase strategy through to commercial readiness.
Its purpose-built GMP facility includes four Grade C cleanrooms, a dedicated Fill Finish suite, in-house QC labs and on-site Qualified Persons. With MHRA approval for clinical manufacturing and a global reach, eXmoor is trusted by clients at all stages of development and commercialisation.
Unlike many CDMOs, eXmoor does not retain client IP. Clients maintain full control over their innovations while benefiting from flexible partnership, transparency and continuity across teams. eXmoor provides the support and freedom innovators need to focus on what matters most: getting life-changing treatments to patients faster.
Our services:
- Consulting: CMC Strategy, CoGs, GMP Compliance, QP, risk assessment.
- Process development for scalable and compliant manufacturing of cells, RNA and vectors.
- Analytical development, testing services, process development data, QC.
- Flexible GMP manufacturing at clinical and commercial scale, fill and finish.
- Consultancy for GMP facility design and process engineering.
